Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.
Please note: Adobe Flash is needed to view webcasts. To download the latest version of Adobe Flash Player, please go to http://get.adobe.com/flashplayer/.
Clinical Management of Prior Nonresponders: A Case-Based Panel Discussion
Request for grants has been made to commercial companies with competing products. Support is from the following:
Gilead Sciences, Inc
Merck & Co, Inc
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
IAS–USA Board of Directors
Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (Updated 04/14/14)
Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)
Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. and has served as a consultant to Gilead Sciences, Inc, and ViiV Healthcare. (Updated 02/4/14)
Carlos del Rio, MD
Dr del Rio has no relevant financial affiliations to disclose. (Updated 03/25/14)
Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant or advisor to Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and Takara Bio Inc; and has received research grants or contracts awarded to his institution from Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Sangamo BioSciences, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 02/24/14)
Roy M. Gulick, MD, MPH
Dr Gulick serves as a co-investigator on research grants awarded to Weill Cornell Medical College from GlaxoSmithKline/ViiV Healthcare. (Updated 04/15/14)
Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/16/14)
Douglas D. Richman, MD
Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe, Inc, Gilead Sciences, Inc, Sirenas, Prism and Monogram Biosciences, Inc. He owns stock from Chimerix. (Updated 03/25/14)
Michael S. Saag, MD
Dr Saag has received grants and research support from Abbvie, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. (Updated 03/21/14)
Robert T. Schooley, MD
Dr Schooley has received research support from Bristol-Myers Squibb and Boehringer Ingelheim Pharmaceuticals, Inc, and has served as a scientific advisor to CytoDyn and Merck & Co, Inc, as a scientific advisory board member for Gilead Sciences, Inc, GlobeImmune, Inc, and Monogram Biosciences, and as a member of data monitoring committees for Axio and Gilead Sciences, Inc. He has stock in GlobeImmune, Inc. (Updated 04/07/14)
Paul A. Volberding, MD
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 02/04/14)
Course Faculty and Staff:
Dr Kiser has received research support from GlaxoSmithKline, Janssen, Merck & Co, Inc, and Vertex Pharmaceuticals, Inc. She has served as a consultant for Bristol Myers Squibb. (Updated 10/30/12)
Dr Kuo has no relevant financial affiliations to disclose. (Updated 10/29/12)
Dr Osborn has received payment for development of educational presentations for Medscape. (Updated 10/29/12)
Dr Peters has served as a consultant to Merck & Co, Inc, Theravance, and Roche. She has served on data safety monitoring board for Biotron. She has served as a scientific advisor to Clinical Care Options. Her spouse is employed by Genentech Research and Development, owned by Roche. (Updated 10/29/12)
Dr Wyles has received grants awarded to the University of California San Diego from Gilead Sciences, Inc, Pharmasset, Inc, Merck & Co, Inc. and Vertex Pharmaceuticals. He also served as a consultant to Bristol-Myers Squibb, Janssen Pharmaceuticals, Inc, and Merck & Co, Inc. He has developed educational presentations for QuantiaMD. (Updated 10/31/12)
IAS–USA CME Staff
Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).
Cristin M. Toth, CME Project Manager, has no relevant financial affiliations to disclose. (Updated 04/26/14)
CME Evaluation and Claim Forms
After viewing this webcast, please submit your evaluation form to claim credit.